-
1
Supplementary Table S4 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Baskı/Yayın Bilgisi 2025Diğer Yazarlar: “…Frederick S. Vizeacoumar (14851118)…”
-
2
Supplementary Table S7 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Baskı/Yayın Bilgisi 2025Diğer Yazarlar: “…Frederick S. Vizeacoumar (14851118)…”
-
3
Supplementary Table S5 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Baskı/Yayın Bilgisi 2025Diğer Yazarlar: “…Frederick S. Vizeacoumar (14851118)…”
-
4
Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Baskı/Yayın Bilgisi 2025Diğer Yazarlar: “…Frederick S. Vizeacoumar (14851118)…”
-
5
Supplementary Table S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Baskı/Yayın Bilgisi 2025Diğer Yazarlar: “…Frederick S. Vizeacoumar (14851118)…”
-
6
Supplementary Table S1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Baskı/Yayın Bilgisi 2025Diğer Yazarlar: “…Frederick S. Vizeacoumar (14851118)…”
-
7
Supplementary Table S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Baskı/Yayın Bilgisi 2025Diğer Yazarlar: “…Frederick S. Vizeacoumar (14851118)…”